Multiple Myeloma Therapeutics in Major Developed Markets to 2021

1
Multiple Myeloma Therapeutics in Major Developed
Markets to 2021
No. Pages 119
Published on July - 2015
2
.
Report Overview
About Multiple Myeloma Therapeutics in Major
Developed Markets to 2021 Research Beam added a
report Multiple Myeloma Therapeutics in Major
Developed Markets to 2021. Multiple Myeloma
Therapeutics in Major Developed Markets to 2021 -
Growth Driven by Rising Prevalence, Continued
Success of Revlimid and Emerging Supplementary
Treatments Summary Multiple Myeloma (MM) is a
hematological malignancy characterized by the
proliferation of plasma cells in the bone marrow.
It is the second-most frequently diagnosed
hematological malignancy, with an annual
prevalence in the US of about 45,000. The disease
is considered incurable, although the past decade
has seen significant improvements in therapy,
driven by a greater understanding of
pathophysiology. Many of the leading drugs in the
market were approved over the past 1015 years,
and have improved median survival rates by about
50. Get Full Details On http//www.researchbeam
.com/multiple-myeloma-therapeutics-in-major-develo
ped-to-2021-growth-driven-by-rising-prevalence-con
tinued-success-of-revlimid-and-emerging-supplement
ary-treatments-market
3
.
Report Overview

• The MM pipeline contains 267 products in active
  development, encompassing a range of molecule
  types and therapeutic targets. The innovation
  that has characterized the market over recent
  years is also clearly present in the current
  pipeline, with a strong presence of novel,
  targeted products.
• Scope
• The MM market landscape has undergone significant
  change over the past two decades.
• Which classes of drug have emerged to dominate
  the market?
• What survival benefits have these drugs produced?
• How do the leading marketed therapies compare
  clinically?
• The pipeline contains a range of molecule types
  and molecular targets not present in the current
  market, including a strong focus on therapies
  targeting common oncogenic pathways, such as the
  Phosphoinositide 3-Kinase/Protein Kinase B
  (PI3K/Akt) pathway.
• Which molecular targets appear most frequently in
  the pipeline?
• How will the new therapies be positioned in the
  treatment of MM?

4
.
Report Overview

• How have selected late-stage pipeline therapies
  performed in clinical trials?
• MM clinical trials have an overall attrition rate
  of 78.
• What are the failure rates for individual Phases
  of clinical development?
• How do MM clinical trial characteristics,
  including failure rate, duration, and size
  compare against oncology and industry averages?
• The MM market is forecast to rise from a value of
  7.3 billion in 2014 to 8.9 billion in 2021, at
  a CAGR of 2.9 across the eight major markets
  assessed.
• How much of a role will disease prevalence and
  new product approvals play in market growth?
• Will generic competition have a significant
  impact on the market over the forecast period?
• There have been 39 licensing deals and 22
  co-development deals pertaining to MM products
  since 2006.
• Which territories show the most deal activity?
• What were the trends in deal completion by
  product stage of development?
• What were the conditions of the key licensing or
  co-development deals to take place in MM?

5
Report Overview

• Reasons to buy
• Understand the current clinical and commercial
  landscape through a comprehensive study of
  disease pathogenesis, diagnosis, prognosis, and
  the current treatment algorithm used in MM.
• -Assess the safety and efficacy of current
  treatment options, with extensive product
  profiles on prominent marketed therapies and a
  heat map directly comparing safety and efficacy
  data.
• Analyze the MM pipeline and stratify by stage of
  development, molecule type, and molecular target.
  The most promising late-stage therapies are
  profiled and assessed in terms of clinical
  performance and competitiveness, alongside a
  single-product forecast.
• Predict growth in market size in eight major
  markets, with in-depth market forecasting from
  20142021. The forecasts will provide an
  understanding of how epidemiology trends, new
  drug entry, and patent expirations will influence
  market value.
• Identify commercial opportunities in the MM deals
  landscape by analyzing trends in licensing and
  co-development deals, and by profiling the most
  significant deals that have occurred in this
  indication in recent years.
•  

6
Table Of Contents
1 Table of Contents1 Table of Contents 41.1
List of Tables 61.2 List of Figures 72
Introduction 92.1 Disease Introduction 92.2
Etiology 92.3 Pathophysiology 92.4 Symptoms
112.5 Diagnosis and Classification 112.6
Epidemiology 142.7 Prognosis and Disease Staging
152.8 Treatment Options 172.8.1 Treatment
Algorithm 19
7
Table Of Contents
2.8.2 Initial Therapy for Newly Diagnosed
Symptomatic Disease 192.8.3 Maintenance Therapy
222.8.4 Therapy for Relapsed or Refractory
Myeloma 243 Marketed Products 293.1 Overview
293.2 Immunomodulatory Agents 293.2.1 Thalomid
(thalidomide) â Celgene 293.2.2 Revlimid
(lenalidomide) â Celgene 303.2.3 Pomalyst
(pomalidomide) â Celgene 303.3 Proteasome
Inhibitors 313.3.1 Velcade (bortezomib) â
Millennium Pharmaceuticals/Takeda 313.3.2
Kyprolis (carfilzomib) â Onyx 313.4 Histone
Deacetylase Inhibitors 32
8
Table Of Contents
3.5.1 Doxil (doxorubicin HCl liposome injection)
â Janssen 323.6 Comparative Efficacy and
Safety of Marketed Products 334 Pipeline
Products 384.1 Overall Pipeline 384.2 Pipeline
Analysis by Molecular Target 394.3 Clinical
Trials 424.3.1 Failure Rate 434.3.2 Patient
Enrolment and Clinical Trial Size 454.3.3
Duration 50Enquiry about this report _at_
http//www.researchbeam.com/multiple-myeloma-thera
peutics-in-major-developed-to-2021-growth-driven-b
y-rising-prevalence-continued-success-of-revlimid-
and-emerging-supplementary-treatments-market/enqui
re-about-report
9
FOR MORE DETAILS
Visit us at
http//www.researchbeam.com/multiple-myeloma-thera
peutics-in-major-developed-to-2021-growth-driven-b
y-rising-prevalence-continued-success-of-revlimid-
and-emerging-supplementary-treatments-market
Stay With Us
5933 NE Win Sivers Drive,205, Portland, OR
97220United States
TELEPHONE [phone] E-MAIL
sales_at_researchbeam.com